



Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

April 27, 2022

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- **Advaxis, Inc. (OTCQX: ADXS)**, a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it will present data from the Phase 2 study of ADXS-503 in combination with pembrolizumab in patients with metastatic non-small cell lung cancer and data from the Phase 1 study of ADXS-504 in patients with biochemically recurrent prostate cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 3-7, 2022.

Presentation Details:

Abstract #1

Title: A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non-small cell lung cancer either progressing on prior pembrolizumab or in the first line setting.

Session Type: Poster Session

Abstract Number: 9038

Date and Time: June 6, 2022, 8-11 AM (CDT)

Abstract #2

Title: Immunogenicity and disease control induced by a multi-neoantigen vaccine (ADXS-503) in patients with metastatic non-small cell lung cancer who have progressed on pembrolizumab.

Session Type: Poster Session

Abstract Number: 9042

Date and Time: June 6, 2022, 8-11 AM (CDT)

Abstract #3

Title: A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.

Session Type: Poster Session

Abstract Number: TPS5115

Date and Time: June 6, 2022, 1:15-4:15 CDT (CDT)

About Advaxis, Inc.

Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes* (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements that express the current beliefs and expectations of management, including but not limited to statements related to the expected clinical development of the Company's drug product candidates, statements about the Company's balance sheet position, and statements related to the goals, plans and expectations for the Company's ongoing clinical studies. These and other risks are discussed in the Company's filings with the SEC, including, without limitation, its Annual Report on Form 10-K, filed on February 14, 2022, and its periodic reports on Form 10-Q and Form 8-K. Any statements contained herein that do not describe historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.

Investor Contact

Tim McCarthy

LifeSci Advisors, LLC

Tim@lifesciadvisors.com

(212) 915-2564



Source: Advaxis, Inc.